These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6814639)

  • 21. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents.
    Conwell LS; Pope E; Artiles AM; Mohanta A; Daneman A; Daneman D
    J Pediatr; 2008 May; 152(5):622-8. PubMed ID: 18410763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans.
    Clausen TS; Kaastrup P; Stallknecht B
    Diabetes Technol Ther; 2009 Sep; 11(9):575-80. PubMed ID: 19764836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin lipohypertrophy.
    Schiazza L; Occella C; Bleidl D; Rampini E
    J Am Acad Dermatol; 1990 Jan; 22(1):148-9. PubMed ID: 2076114
    [No Abstract]   [Full Text] [Related]  

  • 24. [Localized lipohypertrophy during growth hormone therapy].
    Mersebach H; Feldt-Rasmussen UF
    Ugeskr Laeger; 2002 Apr; 164(14):1930-2. PubMed ID: 11957429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro (Humalog).
    Roper NA; Bilous RW
    Diabet Med; 1998 Dec; 15(12):1063-4. PubMed ID: 9868982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipohypertrophy and glomerulonephritis after the use of aprotinin in an insulin-dependent diabetic.
    Boag F; Chappell M; Beckett AG; Dandona P
    N Engl J Med; 1985 Jan; 312(4):245-6. PubMed ID: 2578215
    [No Abstract]   [Full Text] [Related]  

  • 27. Fatalities Due to Failure of Continuous Subcutaneous Insulin Infusion Devices: A Report of Six Cases.
    Ziegler A; Williams T; Yarid N; Schultz DL; Bundock EA
    J Forensic Sci; 2019 Jan; 64(1):275-280. PubMed ID: 29940703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxic-shock syndrome in a patient using a continuous subcutaneous insulin infusion pump--Idaho.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1983 Aug; 32(31):404-6, 412. PubMed ID: 6410172
    [No Abstract]   [Full Text] [Related]  

  • 29. [The treatment of type-1 diabetics with insulin-induced lipohypertrophy by liposuction].
    Hauner H; Olbrisch RR
    Dtsch Med Wochenschr; 1994 Mar; 119(12):414-7. PubMed ID: 8143555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycobacterium fortuitum infection in continuous subcutaneous insulin infusion sites.
    López Aventín D; Rubio González B; Petiti Martín G; Segura S; Rodríguez-Peralto JL; Riveiro-Falkenbach E; Puig J; Pujol RM
    Br J Dermatol; 2014 Aug; 171(2):418-20. PubMed ID: 24588257
    [No Abstract]   [Full Text] [Related]  

  • 31. [Ketoacidosis during ambulatory treatment by continuous subcutaneous infusion of insulin. Possible role of catheter infection].
    Leguerrier AM; Allannic H; Lorcy Y
    Presse Med; 1984 Apr; 13(16):1008. PubMed ID: 6232520
    [No Abstract]   [Full Text] [Related]  

  • 32. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance.
    Kelley DE; Thaete FL; Troost F; Huwe T; Goodpaster BH
    Am J Physiol Endocrinol Metab; 2000 May; 278(5):E941-8. PubMed ID: 10780952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leads from the MMWR. Toxic-shock syndrome in a patient using a continuous subcutaneous insulin infusion pump--Idaho.
    JAMA; 1983 Sep; 250(9):1134-5. PubMed ID: 6876350
    [No Abstract]   [Full Text] [Related]  

  • 34. [Diabetic ketoacidosis during insulin pump therapy].
    Walter H; Günther A; Timmler R; Mehnert H
    Dtsch Med Wochenschr; 1989 May; 114(18):706-8. PubMed ID: 2496965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Insulin-induced lipohypertrophy treated by liposuction].
    Brun A; Comparin JP; Voulliaume D; Chekaroua K; Foyatier JL; Perrot P
    Ann Chir Plast Esthet; 2007 Jun; 52(3):218-21. PubMed ID: 17382444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding continuous subcutaneous insulin infusion therapy.
    Savinetti-Rose B; Bolmer L
    Am J Nurs; 1997 Mar; 97(3):42-8; quiz 48-9. PubMed ID: 9055761
    [No Abstract]   [Full Text] [Related]  

  • 37. Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study.
    Renard E; Guerci B; Leguerrier AM; Boizel R;
    Diabetes Technol Ther; 2010 Oct; 12(10):769-73. PubMed ID: 20809682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Single-Center Long-Term Continuous Subcutaneous Insulin Infusion (CSII) Experience: Higher Fractional Use Is Associated With Less Diabetes Complications.
    Tubili C; Folco UD; Nardone MR; Clementi A
    J Diabetes Sci Technol; 2017 Sep; 11(5):1057-1058. PubMed ID: 28367635
    [No Abstract]   [Full Text] [Related]  

  • 39. [Comparative study between the subcutaneous continuous insulin infusion pump and optimized conventional treatment. Effects at 6 months].
    Goicolea Opacua I; Hernández Colau I; Vázquez García JA
    Rev Clin Esp; 1986 Jun; 179(1):3-7. PubMed ID: 3526432
    [No Abstract]   [Full Text] [Related]  

  • 40. [Continuous subcutaneous insulin infusion].
    Ito H; Kanatsuka A
    Nihon Rinsho; 1997 Nov; 55 Suppl():267-72. PubMed ID: 9434479
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.